A personalized approach to cancer treatment: How biomarkers can help

Clinical Chemistry

Volumn 54, Issue 11, 2008, Pages 1770-1779

  Duffy, Michael J ^a,b   Crown, John ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALPHA FETOPROTEIN; ANTHRACYCLINE; ASPARAGINASE; BIOLOGICAL MARKER; CETUXIMAB; CHORIONIC GONADOTROPIN; DAUNORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; FLUOROURACIL; GEFITINIB; GLUCURONOSYLTRANSFERASE; IMATINIB; IRINOTECAN; LACTATE DEHYDROGENASE; PACLITAXEL; PANITUMUMAB; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDNISOLONE; PROGESTERONE RECEPTOR; STEM CELL FACTOR RECEPTOR; TAMOXIFEN; THIOPURINE METHYLTRANSFERASE; TRASTUZUMAB; UNINDEXED DRUG; UROKINASE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DISEASE MARKER; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE EXPRESSION; GERM CELL TUMOR; GLIOMA; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LOW DRUG DOSE; LUNG CANCER; MARKER GENE; MEDICAL DECISION MAKING; MICROARRAY ANALYSIS; MONOTHERAPY; MULTIGENE FAMILY; NON SEMINOMATOUS GERMINOMA; OVARY CANCER; PATIENT SELECTION; PRACTICE GUIDELINE; PREDICTION; PROGNOSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEOMICS; REVIEW; TISSUE LEVEL; TREATMENT RESPONSE;

HUMANS; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 55349099142     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2008.110056     Document Type: Review

References (76)

1. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005;23:2020-7.
2. Burke HB. Outcome prediction and the future of the TNM staging system. J Natl Cancer Inst 2004;96:1408-9.
3. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 2005;23:32-41.
4. Ioannidis JPA. Is molecular profiling ready for use in clinical decision making. Oncologist 2007;12:301-11.
5. Kyzas PA, Denaxa-Kyza D, Ioannidis JPA. Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. J Natl Cancer Inst 2007;99:236-43.
6. Duffy MJ. Role of tumor markers in patients with solid cancers: a critical review. Eur J Int Med 2007;18:175-84.
7. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603.
8. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M. AJCC Cancer Staging Manual. 6th Edition. New York: Springer-Verlag, 2000.
9. Sobin LH, Wittekind Ch, editors. TNM Classification of Malignant Tumors. 6th ed. UICC (International Union Against Cancer). New York: Wiley-Liss, 2002.
10. Lamerz R, Albrecht W, Bialk P, Dati F, Duffy MJ, Gerl E, et al. Tumor markers in germ cell cancers: EGTM recommendations. Anticancer Res 1999;19:2795-8.
11. The National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines and Recommendations for Use of Tumor Markers in The Clinic. http://www.aacc.org/members/nacb/LMPG/OnlineGuide/DraftGuidelines/TumorMarkers/ Pages/default.aspx (Accessed August 2008).
12. Loeb S, Catalona WJ. Prostate-specific antigen in clinical practice. Cancer Lett 2007;249:30-9.
13. Duffy MJ. CEA as a marker for colorectal cancer: is it clinically useful? Clin Chem 2001;47:624-30.
14. Board RE, Bruijns CTPH, Pronk AE, Ryder WD, Wilkinson PM, Welsh R, et al. Stage- and CA 125-related survival in patients with epithelial ovarian cancer treated at a cancer center. Int J Gynecol Cancer. 2006;16(Suppl 1):18-24.
15. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 2006;52:345-51.
16. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003;8:307-25.
17. Mirza AN, Mirza NQ, Vlastos G, Singletary E. Prognostic factors in mode-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002;235:10-26.
18. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133-44.
19. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer: European Group of Tumor Markers (EGTM) recommendations. Tumor Biol 2005;26:281-93.
20. Harris L, Fritsche H, Menel R, Norton L, Ravidin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-312.
21. Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Sweep F, et al., for the German Chemo N0 Study Group. Randomized adjuvant chemotherapy trial in high-risk node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001;93:913-20.
22. Look MP, van Putten WLJ, Duffy MJ, Harbeck N, Christensen U, Thomssen C, et al. Pooled analysis of prognostic impact of tumor biological factors uPA and PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002;94:116-28.
23. Hayes DF, Bast R, Desch CE, Fritsche H, Kemeny NE, Jessup JM, et al. A tumor marker utility grading system (TMUGS): a framework to evaluate clinical utility of tumor markers. J. Natl Cancer Inst 1996;88:1456-66.
24. Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 2007;99:147-57.
25. van't Veer LJ, Dai H, van deVijer MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature (Lond) 2002;415:530-6.
26. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
27. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, et al., Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006;98:1183-92.
28. Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT Trial. J Clin Oncol 2008;26:729-35.
29. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multi-gene assay to predict recurrence of tamoxifen-treated node-negative breast cancer. N Engl J Med 2005;347:2817-26.
30. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34.
31. Sparano JA. TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer 2006;7:347-50.
32. Duffy MJ, Kelly ZD, Culhabe AC, O'Brien SL, Gallagher WM. DNA microarray-based gene expression profiling in cancer: aiding cancer diagnosis, assessing prognosis and predicting response to therapy. Current Pharmacogenomics 2005;3:289-304.
33. Duffy MJ. Predictive markers in breast and other cancers: a review. Clin Chem 2005;51:494-503.
34. Duffy MJ. Estrogen receptors: role in breast cancer. Crit Rev Clin Lab Sci 2006;43:325-47.
35. Ring A, Dowsett M. Mechanism of tamoxifen resistance. Endocr Rel Cancer 2004;11:647-58.
36. Horwitz KB, McGuire WL, Pearson OH, Segaloff A. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science (Wash DC) 1975;189:726-7.
37. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in 2 large breast cancer databases. J Clin Oncol 2003;21:1973-9.
38. Demonty G, Bernard-Marty C, Puglisi F, Mancini I, Piccart M. Progress and new standards of care in the management of HER-2 positive breast cancer. Eur J Cancer 2007;43:497-509.
39. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Sem Oncol 2001;28(Suppl 3):13-9.
40. Moasser MM. Targeting the function of the HER2 oncogene in human cancer therapies. Oncogene 2007;26:6577-92.
41. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, et al. Activity of dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630-9.
42. Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008;100:14-20.
43. 6-methylguanine DNA methyltransferase in human cancer. Oncogene 2004;23:1-8.
44. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4.
45. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
46. 6-methylguanine DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 2007;25:1470-5.
47. Mano MS, Rosa DD, de Azambuja E, Ismael GFV, Durbecq V. The 17q12-q21 amplicon: her2 and topoisomerase-IIa and their importance to the biology of solid tumours. Cancer Treat Rev 2007;33:64-77.
48. Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmstrom P. Topoisomerase IIa gene amplification predicts favourable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: results from the randomised Scandinavian breast group trial 9401. J Clin Oncol 2006;16:2428-36.
49. Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer, search and destroy. Eur J Cancer 2006;42:17-23.
50. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007;25:587-95.
51. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nature (Lond) Rev Cancer 2007;7:169-81.
52. Uramoto H, Mitsudomi T. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer. Br J Cancer 2007;96:857-63.
53. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 2005;102:8315-20.
54. Bhat KMR, Setaluri V. Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res 2007;13:2849-54.
55. Andre F, Hatzis C, Anderson K, Sitiriou C, Mazouni C, Mejia J, et al. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 2007;13:2061-7.
56. Chang JC, Wooten EC, Tsimeizon A, Hilsenbeck SG, Gutierrez MC, Elledge R, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362:362-9.
57. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004;22:2284-93.
58. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006;24:4236-44.
59. Peintinger F, Anderson K, Mazouni C, Kuerer HM, Hatzis C, Lin F, et al. Thirty gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer. Clin Cancer Res 2007;13:4078-82.
60. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, et al. Kinase mutation and imatinib response in patients with metastatic gastrointestinal stromal tumors. J Clin Oncol 2003;21:4342-9.
61. Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, et al. Use of c-KIT/PDGRFA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40:689-95.
62. Lievre A, Bachet J-P, Le Corre DL, Boige V, Landi B, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
63. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-7.
64. Lievre A, Bachet J-B, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9.
65. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
66. Holleman A, Cheok MH, den Boer ML, Yang W, Veerman AJP, Kazemier et al. Gene expression pattern in drug-resistant acute lymphoblastic leukaemia cells and response to treatment. N Engl J Med 2004;351:533-42.
67. Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CE. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006;98:1108-17.
68. Lee W, Lockhart C, Kim RB, Rothenberg ML. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 2005;10:104-11.
69. Ezzeldin HH, Diasio RB. Genetic resting in cancer therapeutics. Clin Cancer Res 2006;12:4137-41.
70. Sanderson J, Ansari A, Marinaki T, Duley J. Thiopurine glucuronosyltransferase (methyltransferase): should it be measured before commencing thiopurine drug therapy. Ann Clin Biochem 2004;41:294-302.
71. O'Dwyer PJ. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 2006;28:4534-8.
72. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007;99:1290-5.
73. Gupta R, Kim JP, Spiegel J, Ferguson SM. Developing products for personalized medicine: NIH research tools policy applications. Future Med 2004;1:115-24.
74. Batchelder K, Miller P. A change in the market, investing in diagnostics. Nature (Lond) Biotechnol 2006;8:922-6.
75. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nature (Lond) Rev Drug Discovery 2007;6:287-93.
76. Allison M. Is personalized medicine finally arriving? Nature (Lond) Biotechnol 2008;26:509-17.